Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Work In Process (2020 - 2025)

Karyopharm Therapeutics' Work In Process history spans 6 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Work In Process fell 15.87% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, down 15.87%, while the annual FY2025 figure was $3.0 million, 15.87% down from the prior year.
  • Work In Process reached $3.0 million in Q4 2025 per KPTI's latest filing, up from $2.9 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $4.2 million in Q2 2025 to a low of $781000.0 in Q1 2021.
  • Average Work In Process over 5 years is $2.3 million, with a median of $1.9 million recorded in 2021.
  • Peak YoY movement for Work In Process: surged 193.34% in 2021, then plummeted 40.68% in 2023.
  • A 5-year view of Work In Process shows it stood at $1.9 million in 2021, then dropped by 0.9% to $1.9 million in 2022, then decreased by 7.77% to $1.7 million in 2023, then soared by 104.5% to $3.5 million in 2024, then dropped by 15.87% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Work In Process are $3.0 million (Q4 2025), $2.9 million (Q3 2025), and $4.2 million (Q2 2025).